相关实验视频

Updated: May 10, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

高通量向药物查NF1相关的ATRX缺乏的高度质瘤

Swati Dubey¹, Simran Rai¹, Fabiola Guillen¹

¹Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.

bioRxiv : the preprint server for biology

|July 15, 2025

概括

一种新的化合物,K784-6195,可以选择性地杀死具有ATRX突变的神经纤维瘤类型1 (NF1) 患者的高等级质瘤 (HGGs). 这种向治疗破坏了关键的代谢途径,为这种侵袭性脑癌提供了一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

具有ATRX突变的1型神经纤维素瘤 (NF1) 相关的高度质瘤 (HGG) 是具有攻击性的,由基因组不稳定性和代谢重编程驱动.
目前的化疗和放射治疗等治疗方法由于耐药性和二次恶性瘤风险,有效性有限.
对于针对这些瘤的特定弱点的新型治疗策略有着至关重要的需求.

研究的目的:

识别小分子,选择性地准HGGs同时ATRX和NF1损失的漏洞.
评估有希望的候选化合物的疗效和作用机制.

主要方法:

对一万个小分子进行了高通量选.
选择性细胞毒性被评估在NF1-关联质瘤细胞系与或没有ATRX缺乏.
用代谢分析来研究药物的作用机制.

主要成果:

K784-6195对具有ATRX缺乏的NF1关联质瘤细胞系表现出明显的选择性细胞毒性 (IC50 = 4.84μM).
野生型ATRX结质瘤细胞显示显著降低敏感性 (IC50 = 37.03 μM),而模仿并发NF1/ATRX损失的ATRX淘汰细胞更容易受到影响 (IC50 = 20-23 μM).
K784-6195治疗损害了酸通路,谷氨酸代谢和氧化还原平衡,诱导氧化应激并降低细胞存活率.

结论:

K784-6195是NF1相关的HGGs与ATRX缺乏症的有前途的治疗候选者.
该化合物通过破坏瘤细胞存活所必需的关键代谢通路提供了有针对性的方法.
进一步开发K784-6195可能会导致对这种侵袭性脑癌的新疗法.

关键词:

ATRX ATRX 在线观看高通量药物查高通量药物查 1型神经纤维素瘤病的一种类型.神经纤维素是一种神经纤维素.精准医学是一门精准的医学.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...